The Breast Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
Featured Content |view more
Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain
When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism ...
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.
Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024
Innovations in breast cancer, targeted therapies, antibody drug conjugates, and kidney cancer
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention
Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.